1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Chemical Drug CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Chemical Drug CDMO Market, by Service Type
8.1.1. API Manufacturing (Small Molecule APIs, Large Molecule APIs)
8.1.1.1. Market Revenue and Forecast
8.1.2. Formulation Development
8.1.2.1. Market Revenue and Forecast
8.1.3. Contract Research & Development (R&D)
8.1.3.1. Market Revenue and Forecast
8.1.4. Regulatory Services
8.1.4.1. Market Revenue and Forecast
8.1.5. Packaging Services
8.1.5.1. Market Revenue and Forecast
9.1. Chemical Drug CDMO Market, by Drug Type
9.1.1. Branded Drugs
9.1.1.1. Market Revenue and Forecast
9.1.2. Generic Drugs
9.1.2.1. Market Revenue and Forecast
9.1.3. Biosimilars
9.1.3.1. Market Revenue and Forecast
9.1.4. Over-the-Counter (OTC) Drugs
9.1.4.1. Market Revenue and Forecast
10.1. Chemical Drug CDMO Market, by Therapeutic Area
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Cardiovascular
10.1.2.1. Market Revenue and Forecast
10.1.3. Neurology
10.1.3.1. Market Revenue and Forecast
10.1.4. Infectious Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Endocrinology
10.1.5.1. Market Revenue and Forecast
11.1. Chemical Drug CDMO Market, by API Type
11.1.1. Small Molecule APIs
11.1.1.1. Market Revenue and Forecast
11.1.2. Large Molecule APIs (Biologics, Biosimilars)
11.1.2.1. Market Revenue and Forecast
11.1.3. Peptide-based APIs
11.1.3.1. Market Revenue and Forecast
11.1.4. Monoclonal Antibodies (mAbs)
11.1.4.1. Market Revenue and Forecast
12.1. Chemical Drug CDMO Market, by Outsourcing Mode
12.1.1. Full-service CDMOs (End-to-End Services from Discovery to Commercialization)
12.1.1.1. Market Revenue and Forecast
12.1.2. Dedicated Capacity CDMOs (Single-client Facility)
12.1.2.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Service Type
13.1.2. Market Revenue and Forecast, by Drug Type
13.1.3. Market Revenue and Forecast, by Therapeutic Area
13.1.4. Market Revenue and Forecast, by API Type
13.1.5. Market Revenue and Forecast, by Outsourcing Mode
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Service Type
13.1.6.2. Market Revenue and Forecast, by Drug Type
13.1.6.3. Market Revenue and Forecast, by Therapeutic Area
13.1.6.4. Market Revenue and Forecast, by API Type
13.1.6.5. Market Revenue and Forecast, by Outsourcing Mode
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Service Type
13.1.7.2. Market Revenue and Forecast, by Drug Type
13.1.7.3. Market Revenue and Forecast, by Therapeutic Area
13.1.7.4. Market Revenue and Forecast, by API Type
13.1.7.5. Market Revenue and Forecast, by Outsourcing Mode
13.2. Europe
13.2.1. Market Revenue and Forecast, by Service Type
13.2.2. Market Revenue and Forecast, by Drug Type
13.2.3. Market Revenue and Forecast, by Therapeutic Area
13.2.4. Market Revenue and Forecast, by API Type
13.2.5. Market Revenue and Forecast, by Outsourcing Mode
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Service Type
13.2.6.2. Market Revenue and Forecast, by Drug Type
13.2.6.3. Market Revenue and Forecast, by Therapeutic Area
13.2.7. Market Revenue and Forecast, by API Type
13.2.8. Market Revenue and Forecast, by Outsourcing Mode
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Service Type
13.2.9.2. Market Revenue and Forecast, by Drug Type
13.2.9.3. Market Revenue and Forecast, by Therapeutic Area
13.2.10. Market Revenue and Forecast, by API Type
13.2.11. Market Revenue and Forecast, by Outsourcing Mode
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Service Type
13.2.12.2. Market Revenue and Forecast, by Drug Type
13.2.12.3. Market Revenue and Forecast, by Therapeutic Area
13.2.12.4. Market Revenue and Forecast, by API Type
13.2.13. Market Revenue and Forecast, by Outsourcing Mode
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Service Type
13.2.14.2. Market Revenue and Forecast, by Drug Type
13.2.14.3. Market Revenue and Forecast, by Therapeutic Area
13.2.14.4. Market Revenue and Forecast, by API Type
13.2.15. Market Revenue and Forecast, by Outsourcing Mode
13.3. APAC
13.3.1. Market Revenue and Forecast, by Service Type
13.3.2. Market Revenue and Forecast, by Drug Type
13.3.3. Market Revenue and Forecast, by Therapeutic Area
13.3.4. Market Revenue and Forecast, by API Type
13.3.5. Market Revenue and Forecast, by Outsourcing Mode
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Service Type
13.3.6.2. Market Revenue and Forecast, by Drug Type
13.3.6.3. Market Revenue and Forecast, by Therapeutic Area
13.3.6.4. Market Revenue and Forecast, by API Type
13.3.7. Market Revenue and Forecast, by Outsourcing Mode
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Service Type
13.3.8.2. Market Revenue and Forecast, by Drug Type
13.3.8.3. Market Revenue and Forecast, by Therapeutic Area
13.3.8.4. Market Revenue and Forecast, by API Type
13.3.9. Market Revenue and Forecast, by Outsourcing Mode
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Service Type
13.3.10.2. Market Revenue and Forecast, by Drug Type
13.3.10.3. Market Revenue and Forecast, by Therapeutic Area
13.3.10.4. Market Revenue and Forecast, by API Type
13.3.10.5. Market Revenue and Forecast, by Outsourcing Mode
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Service Type
13.3.11.2. Market Revenue and Forecast, by Drug Type
13.3.11.3. Market Revenue and Forecast, by Therapeutic Area
13.3.11.4. Market Revenue and Forecast, by API Type
13.3.11.5. Market Revenue and Forecast, by Outsourcing Mode
13.4. MEA
13.4.1. Market Revenue and Forecast, by Service Type
13.4.2. Market Revenue and Forecast, by Drug Type
13.4.3. Market Revenue and Forecast, by Therapeutic Area
13.4.4. Market Revenue and Forecast, by API Type
13.4.5. Market Revenue and Forecast, by Outsourcing Mode
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Service Type
13.4.6.2. Market Revenue and Forecast, by Drug Type
13.4.6.3. Market Revenue and Forecast, by Therapeutic Area
13.4.6.4. Market Revenue and Forecast, by API Type
13.4.7. Market Revenue and Forecast, by Outsourcing Mode
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Service Type
13.4.8.2. Market Revenue and Forecast, by Drug Type
13.4.8.3. Market Revenue and Forecast, by Therapeutic Area
13.4.8.4. Market Revenue and Forecast, by API Type
13.4.9. Market Revenue and Forecast, by Outsourcing Mode
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Service Type
13.4.10.2. Market Revenue and Forecast, by Drug Type
13.4.10.3. Market Revenue and Forecast, by Therapeutic Area
13.4.10.4. Market Revenue and Forecast, by API Type
13.4.10.5. Market Revenue and Forecast, by Outsourcing Mode
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Service Type
13.4.11.2. Market Revenue and Forecast, by Drug Type
13.4.11.3. Market Revenue and Forecast, by Therapeutic Area
13.4.11.4. Market Revenue and Forecast, by API Type
13.4.11.5. Market Revenue and Forecast, by Outsourcing Mode
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Service Type
13.5.2. Market Revenue and Forecast, by Drug Type
13.5.3. Market Revenue and Forecast, by Therapeutic Area
13.5.4. Market Revenue and Forecast, by API Type
13.5.5. Market Revenue and Forecast, by Outsourcing Mode
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Service Type
13.5.6.2. Market Revenue and Forecast, by Drug Type
13.5.6.3. Market Revenue and Forecast, by Therapeutic Area
13.5.6.4. Market Revenue and Forecast, by API Type
13.5.7. Market Revenue and Forecast, by Outsourcing Mode
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Service Type
13.5.8.2. Market Revenue and Forecast, by Drug Type
13.5.8.3. Market Revenue and Forecast, by Therapeutic Area
13.5.8.4. Market Revenue and Forecast, by API Type
13.5.8.5. Market Revenue and Forecast, by Outsourcing Mode
14.1. Almac Group
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. BASF SE
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Boehringer Ingelheim
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Cipla Limited
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. DSM Sinochem Pharmaceuticals
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Fujifilm Diosynth Biotechnologies
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Hovione
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Lonza Group
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Mylan (Viatris Inc.)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Patheon (Thermo Fisher Scientific Inc.)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
